Form 4: Agios Pharmaceuticals Executive Theodore James Jr. Washburn Reports Stock Transactions
SEC Form 4
Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.
Summary
- Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On March 1, 2025, Washburn acquired common stock through the exercise of restricted stock units and employee stock purchase plan.
- Washburn also disposed of shares on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock units at a price of $35.54.
- The transactions were executed under a pre-arranged 10b5-1(c) trading plan.
- Following these transactions, Washburn directly owns 9,414 shares of Agios Pharmaceuticals common stock.
- Washburn also holds restricted stock units representing the right to receive 4,900 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions related to stock options and tax obligations, which are routine.
Positives
- The reporting person's transactions are part of a pre-arranged trading plan (Rule 10b5-1(c)), suggesting they are not based on insider information.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. This filing is specific to Agios Pharmaceuticals and one of its officers.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency in insider trading.
- The use of 10b5-1 trading plans is a common strategy among executives to avoid accusations of insider trading, aligning with industry best practices.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| March 1, 2022 | Date of the reporting person's restricted stock unit agreement. |
| March 1, 2023 | Date of the reporting person's restricted stock unit agreement. |
| March 1, 2024 | Date of the reporting person's restricted stock unit agreement. |
| March 1, 2025 | Date of earliest transaction, grant date of restricted stock units, and vesting start date for some units. |
| March 3, 2025 | Date of stock sales to cover tax obligations. |
| March 1, 2026 | Beginning date for vesting of 8,085 restricted stock units in three equal annual installments. |
| February 1, 2027 | Date when 6,142 restricted stock units will vest in full. |
| March 4, 2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.